Epidermal growth factor stimulates prostacyclin production by cultured human vascular endothelial cells.
Epidermal growth factor (EGF) stimulated prostacyclin (PGI2) production by cultured human umbilical vein endothelial cells, as measured by radioimmunoassay of its stable metabolite 6-keto-prostaglandin F1 alpha. This effect of EGF was dose-dependent, the lowest stimulatory concentration of EGF was 1.0 ng/ml and 100 ng/ml caused a 2.7 +/- 0.3 (mean +/- SEM) fold increase in the PGI2 synthesis. The stimulation appeared at 3-6 h of incubation and lasted at least 24 h. It was suppressed by EGF antibodies and blocked by protein synthesis inhibitor cycloheximide. Cells preincubated 12 h with EGF released also higher amounts of PGI2 when incubated with thrombin for 5 min. It is concluded that EGF liberated from platelets during aggregation may prevent local thrombogenesis and atherogenesis by stimulating the release of the antiaggregatory, vasodilatory PGI2 from vascular endothelial cells.
Ristimäki
A
A
Children's Hospital, Helsinki, Finland.
Ylikorkala
O
O
Perheentupa
J
J
Viinikka
L
L
D015121:6-Ketoprostaglandin F1 alpha / Q000378:metabolism; D002478:Cells, Cultured; D003513:Cycloheximide / Q000494:pharmacology; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000378:metabolism; D004815:Epidermal Growth Factor / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D011464:Epoprostenol / Q000096:biosynthesis*; D006801:Humans; D013917:Thrombin / Q000494:pharmacology
D015121:6-Ketoprostaglandin F1 alpha; D004815:Epidermal Growth Factor; D003513:Cycloheximide; D011464:Epoprostenol; D013917:Thrombin